Copyright Reports & Markets. All rights reserved.

Global Recurrent Glioblastoma Multiforme Treatment Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Recurrent Glioblastoma Multiforme Treatment Market Overview

      • 1.1 Product Overview and Scope of Recurrent Glioblastoma Multiforme Treatment
      • 1.2 Recurrent Glioblastoma Multiforme Treatment Segment by Type
        • 1.2.1 Global Recurrent Glioblastoma Multiforme Treatment Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 AU-105
        • 1.2.3 Axitinib
        • 1.2.4 AXL-1717
        • 1.2.5 AZD-7451
        • 1.2.6 Others
      • 1.3 Recurrent Glioblastoma Multiforme Treatment Segment by Application
        • 1.3.1 Recurrent Glioblastoma Multiforme Treatment Consumption Comparison by Application (2014-2025)
        • 1.3.2 Hospital
        • 1.3.3 Clinic
        • 1.3.4 Others
      • 1.3 Global Recurrent Glioblastoma Multiforme Treatment Market by Region
        • 1.3.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size Region
        • 1.3.2 North America Status and Prospect (2014-2025)
        • 1.3.3 Europe Status and Prospect (2014-2025)
        • 1.3.4 China Status and Prospect (2014-2025)
        • 1.3.5 Japan Status and Prospect (2014-2025)
        • 1.3.6 Southeast Asia Status and Prospect (2014-2025)
        • 1.3.7 India Status and Prospect (2014-2025)
      • 1.4 Global Recurrent Glioblastoma Multiforme Treatment Market Size
        • 1.4.1 Global Recurrent Glioblastoma Multiforme Treatment Revenue (2014-2025)
        • 1.4.2 Global Recurrent Glioblastoma Multiforme Treatment Production (2014-2025)

      2 Global Recurrent Glioblastoma Multiforme Treatment Market Competition by Manufacturers

      • 2.1 Global Recurrent Glioblastoma Multiforme Treatment Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global Recurrent Glioblastoma Multiforme Treatment Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers Recurrent Glioblastoma Multiforme Treatment Production Sites, Area Served, Product Types
      • 2.5 Recurrent Glioblastoma Multiforme Treatment Market Competitive Situation and Trends
        • 2.5.1 Recurrent Glioblastoma Multiforme Treatment Market Concentration Rate
        • 2.5.2 Recurrent Glioblastoma Multiforme Treatment Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Recurrent Glioblastoma Multiforme Treatment Production Market Share by Regions

      • 3.1 Global Recurrent Glioblastoma Multiforme Treatment Production Market Share by Regions
      • 3.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Regions (2014-2019)
      • 3.3 Global Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America Recurrent Glioblastoma Multiforme Treatment Production
        • 3.4.1 North America Recurrent Glioblastoma Multiforme Treatment Production Growth Rate (2014-2019)
        • 3.4.2 North America Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe Recurrent Glioblastoma Multiforme Treatment Production
        • 3.5.1 Europe Recurrent Glioblastoma Multiforme Treatment Production Growth Rate (2014-2019)
        • 3.5.2 Europe Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China Recurrent Glioblastoma Multiforme Treatment Production (2014-2019)
        • 3.6.1 China Recurrent Glioblastoma Multiforme Treatment Production Growth Rate (2014-2019)
        • 3.6.2 China Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan Recurrent Glioblastoma Multiforme Treatment Production (2014-2019)
        • 3.7.1 Japan Recurrent Glioblastoma Multiforme Treatment Production Growth Rate (2014-2019)
        • 3.7.2 Japan Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global Recurrent Glioblastoma Multiforme Treatment Consumption by Regions

      • 4.1 Global Recurrent Glioblastoma Multiforme Treatment Consumption by Regions
      • 4.2 North America Recurrent Glioblastoma Multiforme Treatment Consumption (2014-2019)
      • 4.3 Europe Recurrent Glioblastoma Multiforme Treatment Consumption (2014-2019)
      • 4.4 China Recurrent Glioblastoma Multiforme Treatment Consumption (2014-2019)
      • 4.5 Japan Recurrent Glioblastoma Multiforme Treatment Consumption (2014-2019)

      5 Global Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price Trend by Type

      • 5.1 Global Recurrent Glioblastoma Multiforme Treatment Production Market Share by Type (2014-2019)
      • 5.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type (2014-2019)
      • 5.3 Global Recurrent Glioblastoma Multiforme Treatment Price by Type (2014-2019)
      • 5.4 Global Recurrent Glioblastoma Multiforme Treatment Production Growth by Type (2014-2019)

      6 Global Recurrent Glioblastoma Multiforme Treatment Market Analysis by Applications

      • 6.1 Global Recurrent Glioblastoma Multiforme Treatment Consumption Market Share by Application (2014-2019)
      • 6.2 Global Recurrent Glioblastoma Multiforme Treatment Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in Recurrent Glioblastoma Multiforme Treatment Business

      • 7.1 Boehringer Ingelheim GmbH
        • 7.1.1 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
        • 7.1.2 Recurrent Glioblastoma Multiforme Treatment Product Introduction, Application and Specification
        • 7.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 Boston Biomedical, Inc.
        • 7.2.1 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
        • 7.2.2 Recurrent Glioblastoma Multiforme Treatment Product Introduction, Application and Specification
        • 7.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 Bristol-Myers Squibb Company
        • 7.3.1 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
        • 7.3.2 Recurrent Glioblastoma Multiforme Treatment Product Introduction, Application and Specification
        • 7.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 Cantex Pharmaceuticals, Inc.
        • 7.4.1 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
        • 7.4.2 Recurrent Glioblastoma Multiforme Treatment Product Introduction, Application and Specification
        • 7.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 Cavion LLC
        • 7.5.1 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
        • 7.5.2 Recurrent Glioblastoma Multiforme Treatment Product Introduction, Application and Specification
        • 7.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served
      • 7.6 Celldex Therapeutics, Inc.
        • 7.6.1 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
        • 7.6.2 Recurrent Glioblastoma Multiforme Treatment Product Introduction, Application and Specification
        • 7.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.6.4 Main Business and Markets Served
      • 7.7 Coherus BioSciences, Inc.
        • 7.7.1 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
        • 7.7.2 Recurrent Glioblastoma Multiforme Treatment Product Introduction, Application and Specification
        • 7.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.7.4 Main Business and Markets Served
      • 7.8 Cortice Biosciences, Inc.
        • 7.8.1 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
        • 7.8.2 Recurrent Glioblastoma Multiforme Treatment Product Introduction, Application and Specification
        • 7.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.8.4 Main Business and Markets Served
      • 7.9 Eisai
        • 7.9.1 Eisai Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
        • 7.9.2 Recurrent Glioblastoma Multiforme Treatment Product Introduction, Application and Specification
        • 7.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.9.4 Main Business and Markets Served
      • 7.10 Eli Lilly and Company
        • 7.10.1 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Production Sites and Area Served
        • 7.10.2 Recurrent Glioblastoma Multiforme Treatment Product Introduction, Application and Specification
        • 7.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.10.4 Main Business and Markets Served
      • 7.11 EnGeneIC Ltd
      • 7.12 ERC Belgium SA
      • 7.13 GenSpera, Inc.
      • 7.14 Genzyme Corporation
      • 7.15 GW Pharmaceuticals Plc
      • 7.16 ImmunoCellular Therapeutics, Ltd.

      8 Recurrent Glioblastoma Multiforme Treatment Manufacturing Cost Analysis

      • 8.1 Recurrent Glioblastoma Multiforme Treatment Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of Recurrent Glioblastoma Multiforme Treatment
      • 8.4 Recurrent Glioblastoma Multiforme Treatment Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 Recurrent Glioblastoma Multiforme Treatment Distributors List
      • 9.3 Recurrent Glioblastoma Multiforme Treatment Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global Recurrent Glioblastoma Multiforme Treatment Market Forecast

      • 11.1 Global Recurrent Glioblastoma Multiforme Treatment Production, Revenue Forecast
        • 11.1.1 Global Recurrent Glioblastoma Multiforme Treatment Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global Recurrent Glioblastoma Multiforme Treatment Price and Trend Forecast (2019-2025)
      • 11.2 Global Recurrent Glioblastoma Multiforme Treatment Production Forecast by Regions (2019-2025)
        • 11.2.1 North America Recurrent Glioblastoma Multiforme Treatment Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe Recurrent Glioblastoma Multiforme Treatment Production, Revenue Forecast (2019-2025)
        • 11.2.3 China Recurrent Glioblastoma Multiforme Treatment Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan Recurrent Glioblastoma Multiforme Treatment Production, Revenue Forecast (2019-2025)
      • 11.3 Global Recurrent Glioblastoma Multiforme Treatment Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2019-2025)
        • 11.3.2 Europe Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2019-2025)
        • 11.3.3 China Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2019-2025)
        • 11.3.4 Japan Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2019-2025)
      • 11.4 Global Recurrent Glioblastoma Multiforme Treatment Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global Recurrent Glioblastoma Multiforme Treatment Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Recurrent Glioblastoma Multiforme Treatment market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Recurrent Glioblastoma Multiforme Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Recurrent Glioblastoma Multiforme Treatment market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        Boehringer Ingelheim GmbH
        Boston Biomedical, Inc.
        Bristol-Myers Squibb Company
        Cantex Pharmaceuticals, Inc.
        Cavion LLC
        Celldex Therapeutics, Inc.
        Coherus BioSciences, Inc.
        Cortice Biosciences, Inc.
        Eisai
        Eli Lilly and Company
        EnGeneIC Ltd
        ERC Belgium SA
        GenSpera, Inc.
        Genzyme Corporation
        GW Pharmaceuticals Plc
        ImmunoCellular Therapeutics, Ltd.

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        AU-105
        Axitinib
        AXL-1717
        AZD-7451
        Others

        Segment by Application
        Hospital
        Clinic
        Others

        Buy now